Antibiotics - Articles and news items

Antibiotic therapy for nearly 1 in 4 adults with pneumonia does not work

Industry news / 22 May 2017 / Niamh Marriott, Junior Editor

Approximately one in four adults prescribed an antibiotic in an outpatient setting for community-acquired pneumonia does not respond to treatment…

SpeeDx logo

SpeeDx and Thermo Fisher Scientific announce strategic partnership for FDA clearance of molecular diagnostic test

Supplier news / 12 May 2017 / SpeeDx Pty. Ltd

ResistancePlus™ MG Test would bring disease and antibiotic resistance testing for potential “superbug”…

Protein targeting antibiotics bring new hope against multi-drug resistance

Industry news / 27 April 2017 / Niamh Marriott, Junior Editor

Polyphor presented promising data for their novel class of antibiotics, the Outer Membrane Protein Targeting Antibiotics (OMPTA)…

A is for Antibiotics

Blog / 14 November 2016 / Niamh Louise Marriott, Digital Content Producer

A is for Antibiotics – the first instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research on the subject of antibiotics.

MicuRx’S Phase III MRSA antibiotic trial to support Chinese NDA filing

Industry news / 20 October 2016 / Niamh Louise Marriott, Digital Content Producer

The recent $55M Series C financing will allow MicuRx to complete this Phase 3 study, and at a vital time with antibiotic resistance at an all time high…

Antibiotics: resist the resistance

Blog, Z Homepage promo / 15 September 2016 / Niamh Louise Marriott, Digital Content Producer

European Pharmaceutical Review caught up with Destiny Pharma’s CEO, Dr Love, for an exclusive interview to discuss why the pharmaceutical industry needs to radically change its approach to antibiotics in order to combat the threat of bacterial resistance…

Alliance to Save our Antibiotics: antimicrobial resistance ‘to kill one person every 3 seconds by 2050’

Blog / 13 September 2016 / Niamh Louise Marriott, Digital Content Producer

Following an article about the worrying presence of E.coli in UK supermarkets, our sister title New Food caught up with Emma Rose from Alliance to Save Our Antibiotics for an exclusive interview discussing the latest issues facing antibiotic resistance…

Destiny’s SA trial shows fast acting antibiotic too quick for disease resistance

Industry news / 5 September 2016 / Niamh Louise Marriott, Digital Content Producer

The two-stage clinical trial studied the safety, tolerability, and efficacy of intra-nasally applied exeporfinium chloride gels. Part 1 yielded safety data in eight volunteers and allowed progression to Part 2 in 48 healthy volunteers with colonised nasal Staphylococcus aureus (SA) bacteria. Part 2 was double-blinded, placebo controlled, and investigated two exeporfinium chloride concentration gels (0.5 & 2.0mg/g) and two viscosities (2% and 4%) applied into the nostrils for 5 days…

Pneumococcal vaccine PnuBioVax safe and immunogenic in Phase I study

Industry news / 30 June 2016 / Victoria White, Digital Content Producer

ImmBio has reported positive results from the First-in-Human study of its novel vaccine, PnuBioVax, against the bacterial pathogen Streptococcus pneumoniae…

Antibiotics resistance Q&A

Antibiotics resistance Q&A

Issue 3 2016 / 30 June 2016 / Caroline Richards

With the rise in drug-resistant bacterial infections heralding a new, dark era of medicine, antibiotics alternatives could one day become the first-line defence against infectious diseases. With the urgent need to find new approaches clear, Caroline Richards, Editor of European Pharmaceutical Review, interviewed Dr. Bjorn Herpers, Chief Medical Advisor of the Dutch biotechnology firm Micreos, to find out more about the company’s targeted antibacterial products. Micreos is developing a lysin called Staphefekt, which specifically targets Staphylococcus aureus, including meticillin-resistant Staphylococcus aureus (MRSA). Dr. Bjorn also serves as Clinical Microbiologist at Public Health Laboratory, Kennemerland…

AstraZeneca’s new antibiotic Zavicefta approved in the EU

Industry news / 28 June 2016 / Victoria White, Digital Content Producer

The EC has granted marketing authorisation for Zavicefta for the treatment of patients with serious Gram-negative bacterial infections…

Phase II study of relebactam in UTIs meets primary endpoint

Industry news / 21 June 2016 / Victoria White, Digital Content Producer

The addition of relebactam is designed to restore activity of imipenem against certain imipenem-resistant strains of Gram-negative bacteria…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...